BIOVIA

Dassault Systèmes provides business and people with virtual universes to imagine sustainable innovations capable of harmonizing product, nature and life.

Make an enquiry

Contact details

Website

Sector

Industry

Address

Phone

Social media

Reconstructing Beirut’s historic buildings with 3D modelling

After historic buildings in the Lebanese capital were damaged in a warehouse explosion last year, a French start-up is supporting the reconstruction effort with high-resolution 3D modelling of key sites.

Transforming Global Laboratory Operations With Electronic Lab Notebooks

Electronic laboratory notebooks (ELNs) facilitate the highly coordinated effort required to produce pharmaceuticals. ELNs, with multiple parts working in unison, provide a single location for all the data associated with each category to access as it moves through various processes. Successfully implementing ELNs across large organizations comes with its set of challenges.

Download White Paper

Accelerating Biopharma Lab Execution With Digitalization

The growing complexity and diversity of their expanding product lines, as well as the acceleration of clinical trial processes, has put Chemistry, Manufacturing and Controls (CMC) teams on the critical path for commercial product launches.

Download White Paper

Digital Lab Documentation Improves Collaboration, Productivity & Reduces Costs

Laboratory organizations need an environment that facilitates and optimizes collaboration, experiment execution, documentation and data management in the different labs from R&D through manufacturing to commercialization. However, many organizations are dealing with outdated systems that result in multiple inefficiencies. Digitizing documentation goes a long way in improving collaboration and productivity while reducing costs.

Download White Paper

Procedure Management Solution Significantly Reduces Compliance Risk

In today’s competitive environment it is the objective of all life science manufacturing companies to minimize
the risks of compliance non-conformance and the significant associated post-event costs. These costs are seen
in human resource non-production time allocations, production delays or halts, and ultimately shut downs and
product recalls with potential fines or consent decrees. The ultimate costs will be seen in the potential impacts to
patients. These costs can mount into the hundreds of millions of dollars and, as such, should be at the forefront
of boardroom discussions.

Download White Paper

Ferring’s Strategic Approach to Content Management

Challenge: Lack of efficiency and compliance risks in documentation.

Download White Paper

The Importance of an Integrated Informatics Solution for Life Science Organizations

The exorbitant cost of bringing a new pharmaceutical product to market in the U.S. is well documented, with estimates as high as 12 years and $ 2.6 billion USD. There are many factors that drive this cost, including rework due to a lack of access to information from previous experiments, loss of intellectual property (IP), and data mining inefficiency. The goal in drug development is to be the “first to file” for approval of a new drug in order to maximize return on investment (ROI) and increase profit potential, all while producing a high-quality product and remaining regulatory compliant.

Download White Paper

3 resultsShow more

Make an enquiry

Download White Paper

Monitor websites in our network

Receive our newsletter Data, insights and analysis delivered to you

Join our newsletter